An airway clearance system includes a bladder, a negative pressure relief valve, a positive pressure relief valve, and a port. The bladder is moveable between an expanded state and a compressed state, and defines a first volume in the expanded state and a second volume in the compressed state. The second volume is less than the first volume. The negative pressure relief valve is in fluid communication with the bladder and configured to supply fluid to the bladder from an atmosphere surrounding the bladder. The positive pressure relief valve is in fluid communication with the bladder and configured to supply fluid to the atmosphere from the bladder. The port is in fluid communication with the bladder and configured to supply fluid from the bladder when the bladder moves to the compressed state and to supply fluid to the bladder when the bladder moves to the expanded state.
An air sampling system configured to detect an air quality metric for a plurality of volumetric regions comprises an air sample return unit, an air flow controller, and at least one sensor. The air sample return unit is configured to independently transfer air from the plurality of regions as a plurality of air samples. The air flow controller is configured to receive each of the plurality of air samples and selectively direct a selected sample to a sensor supply line and the remainder of the samples to a sample purge line. The at least one sensor is configured to measure an air quality metric of the selected sample and communicate the air quality metric to a controller. The remainder of the air samples are directed to the air sample return unit throughout operation.
The present invention relates to isolated Nato3 mutant polypeptides. Methods for stimulating a brain cell to differentiate into a dopaminergic progenitor neuronal cell or a dopaminergic neuron comprises increasing phosphorylation of Nato3 in the brain cells and culturing the brain cells until a progenitor dopaminergic neuronal cell marker or a dopaminergic neuronal cell marker is expressed in the cultured brain cells. Methods for treating Parkinson's disease (PD) in a subject comprises administering to the subject in need thereof, a composition comprising progenitor dopaminergic neuronal cells and/or dopaminergic neuronal cells expressing a Nato3 mutant polypeptide to the brain of the subject.
C07H 21/00 - Composés contenant au moins deux unités mononucléotide comportant chacune des groupes phosphate ou polyphosphate distincts liés aux radicaux saccharide des groupes nucléoside, p.ex. acides nucléiques
C07H 21/04 - Composés contenant au moins deux unités mononucléotide comportant chacune des groupes phosphate ou polyphosphate distincts liés aux radicaux saccharide des groupes nucléoside, p.ex. acides nucléiques avec le désoxyribosyle comme radical saccharide
C07K 14/47 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
C07K 16/00 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux
C07K 16/18 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains
A system for moving an individual between different positions includes a frame (20) including a pivoted seat (40) for receiving and a drive system for at least partially supporting and moving an Individual between different positions. A control circuit (200) is coupled to the drive system and includes a processor programmed to control the drive system to selectively assist in moving an individual between different positions. The seat comprises a pair of seat sections (42, 44) and a pivot mount (60) to move the seat sections in a generally horizontal plane between a position immediately adjacent one another to a position spaced apart from each other to allow an individual to position her/himself between the seat sections and alternately shift her/his weight to allow an operator to position the seat sections under the individual.
A method of treating a disease or condition in a warm blooded mammal which disease or condition is suspected to be associated with a microbial infection, comprising: administering an antimicrobial effective amount of a carboxylic acid amide, its isomers or salts thereof, to a subject who is suspected to be infected with a microbe. In one embodiment, the carboxylic acid amide is trans-3-(naphth-2-yl)-but-2-enoic acid-N-(2-carboxyphenyl)amide.
A61K 31/167 - Amides, p.ex. acides hydroxamiques ayant des cycles aromatiques, p.ex. colchicine, aténolol, progabide ayant l'atome d'azote d'un groupe carboxamide lié directement au cycle aromatique, p.ex. lidocaïne, paracétamol
brevets
